How is ADPKD detected before symptoms develop?
The main way to detect ADPKD early is through imaging — usually an ultrasound, MRI, or CT scan — that looks for cysts on the kidneys. In a large international registry of over 2,100 children and adolescents with ADPKD, 48% were diagnosed through active screening of family members who had no symptoms [3]. Another study of nearly 31,000 adults undergoing routine health check-ups in Japan found that ultrasound screening could identify people with ADPKD who were unaware they had it, estimating a prevalence of 0.068% — higher than the previously reported rate of 0.025% [6]. This means that many cases are picked up by chance during scans done for other reasons.
Genetic testing can also detect ADPKD before symptoms appear, especially in people with a known family history. However, the same registry study found that rates of genetic testing varied widely between countries (from 19% to 75%) and were linked to healthcare spending [3]. So while genetic testing is an option, imaging remains the most common and accessible method for presymptomatic diagnosis.
Who should consider screening before symptoms appear?
Screening is most useful for people with a family history of ADPKD. In a meta-analysis of 24 studies involving nearly 6,000 patients with ADPKD, the overall prevalence of intracranial aneurysms (a serious complication) was 12.6%, and having a family history of aneurysm or bleeding in the brain more than doubled the odds of finding one [1]. The same analysis found that women, people with high blood pressure, and those with more advanced chronic kidney disease (stage 3 or worse) were also at higher risk [1]. This suggests that if you have these risk factors, screening even when you feel fine could catch problems early.
For children, screening is common but raises ethical questions. The registry study noted that 14% of children were diagnosed due to prenatal abnormalities, a number that has been rising since 2000 [3]. Because ADPKD can be detected so early, families need counseling on the implications of knowing the diagnosis before any symptoms occur [3]. The decision to screen children is not straightforward and depends on family preferences and healthcare systems.
Does finding ADPKD early change what happens next?
Yes, early detection can lead to closer monitoring and earlier treatment, which may slow disease progression. For example, a study of 687 adults with ADPKD found that even a sign as simple as asymptomatic pyuria (white blood cells in the urine without symptoms) was linked to faster kidney function decline — about 1.5 mL/min/1.73 m² per year faster — and earlier kidney failure, especially in people with more severe cystic disease [4]. This means that if you are diagnosed early, your doctor can watch for these markers and start interventions sooner.
Similarly, a study of 195 ADPKD patients found that those with asymptomatic kidney stones had a significantly greater decline in kidney function over time (16.5 vs. 12.8 mL/min/1.73 m², p=0.008) [5]. So early detection of ADPKD allows for screening for these complications, even when you have no symptoms.
For children, the picture is more complex. A trial of tolvaptan (a drug that slows kidney decline) in 91 children aged 4–17 found that it was safe and tolerable over one year, but it did not yet prove that starting it early in childhood significantly slows kidney growth or function decline [2]. The authors note that larger, longer studies are needed to know if early treatment in children truly delays kidney failure [2]. So while early detection is possible, the benefits of early treatment in kids are still being studied.
About These Sources
This answer is built on 6 peer-reviewed studies — published from 2021 to 2025, 3 from 2024 or later, 4 in Q1 journals — selected as the most relevant from 9 studies that passed quality screening, drawn from 74 papers retrieved from a database of over 500 million.
Sources used in this answer
Risk factors for unruptured intracranial aneurysms in asymptomatic patients with autosomal dominant polycystic kidney disease: who needs screening? A systematic review and meta-analysis
In a meta-analysis of 24 studies with nearly 6,000 ADPKD patients, the overall prevalence of intracranial aneurysms was 12.6%; risk factors included female sex (OR 1.63), family history of aneurysm or bleeding (OR 2.17), hypertension (OR 1.41), and stage 3+ chronic kidney disease (OR 2.55).
Tolvaptan for Autosomal Dominant Polycystic Kidney Disease in Children: Why, Who, and When?
In a phase 3b randomized trial of tolvaptan in 91 children with ADPKD, the drug was safe and tolerable over one year, but did not show statistically significant effects on kidney volume or function; larger, longer studies are needed.
Insights from ADPedKD, ERKReg and RaDaR registries provide a multi-national perspective on the presentation of childhood autosomal dominant polycystic kidney disease in high- and middle-income countries
In an analysis of over 2,100 children with ADPKD from 32 countries, 48% were diagnosed through asymptomatic family screening, with rates varying from 19% to 75% across countries; genetic testing rates correlated with healthcare spending.
Asymptomatic Pyuria as a Prognostic Biomarker in Autosomal Dominant Polycystic Kidney Disease
In a retrospective cohort of 687 adults with ADPKD, asymptomatic pyuria was associated with faster kidney function decline (about 1.5 mL/min/1.73 m² per year faster) and earlier kidney failure in those with more severe cystic disease.
The impact of asymptomatic kidney stones on disease progression in autosomal dominant polycystic kidney disease.
In a retrospective cohort of 195 ADPKD patients, those with asymptomatic kidney stones had a significantly greater decline in kidney function (ΔeGFR 16.5 vs. 12.8 mL/min/1.73 m², p=0.008) and nephrolithiasis was independently associated with faster decline.
Epidemiological estimates and early detection of polycystic kidney disease by ultrasonographic assessment in Japan.
In a health check-up study of 30,750 adults in Japan, the estimated prevalence of ADPKD was 0.068% (higher than previously reported 0.025%); those with growing cysts had a larger annual eGFR decline.